Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Citius Pharmaceuticals, Inc. CTXR
$1.41
+$0.09 (6.44%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
207686360.00000000
-
week52high
1.71
-
week52low
0.77
-
Revenue
0
-
P/E TTM
-7
-
Beta
1.37647000
-
EPS
-0.20000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 18 янв 2022 г. |
| Maxim Group | Buy | 30 ноя 2021 г. | |
| H.C. Wainwright | Buy | 23 мая 2018 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Kane William | A | 75000 | 75000 | 04 окт 2022 г. |
| Dutia Suren G | A | 75000 | 75000 | 04 окт 2022 г. |
| Mazur Leonard L | A | 550000 | 550000 | 04 окт 2022 г. |
| HOLUBIAK MYRON Z | A | 400000 | 400000 | 04 окт 2022 г. |
| Czuczman Myron | A | 300000 | 300000 | 04 окт 2022 г. |
| Webb Carol | A | 75000 | 75000 | 04 окт 2022 г. |
| Holuka Eugene Myron | A | 75000 | 75000 | 04 окт 2022 г. |
| SAFIR HOWARD | A | 75000 | 75000 | 04 окт 2022 г. |
| Bartushak Jaime | A | 300000 | 300000 | 04 окт 2022 г. |
| SAFIR HOWARD | A | 75000 | 75000 | 11 окт 2021 г. |
Новостная лента
Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023
PRNewsWire
11 янв 2023 г. в 08:30
CRANFORD, N.J. , Jan. 11, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and CEO Leonard Mazur will present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023.
After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR)
Zacks Investment Research
28 дек 2022 г. в 10:51
The heavy selling pressure might have exhausted for Citius Pharmaceuticals, Inc. (CTXR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Citius Pharmaceuticals: Large Price Action Imminent From Catalysts Within 60 Days
Seeking Alpha
08 ноя 2022 г. в 07:36
Citius Pharmaceuticals, Inc. has a handful of catalysts set to occur in the next few months. Of these, some are critical to extending its cash runway far enough to reach commercialization of its major products, and are therefore a "must complete" by the company.
Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
PRNewsWire
08 сент 2022 г. в 16:30
UPDATED: Chairman & CEO of Citius, Leonard Mazur, to present September 12, 2022 at 8:30am ET CRANFORD, N.J. , Sept. 8, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), today announced that Citius will participate in the H.C.
Citius Pharmaceuticals: Hoping For A Turnaround Strategy
Seeking Alpha
05 июл 2022 г. в 18:40
Citius Pharmaceuticals is yet to release test results a year after it was granted positive recommendation by the Independent Data Monitoring Committee (IDMC) to proceed with the planned trial. With the help of Biorasi, Citius could reach full patient enrolment by the end of 2022, as earlier indicated.